AR133230A1 - PHARMACEUTICAL FORMULATIONS FOR INHALATION AND THEIR USES - Google Patents
PHARMACEUTICAL FORMULATIONS FOR INHALATION AND THEIR USESInfo
- Publication number
- AR133230A1 AR133230A1 ARP240101805A ARP240101805A AR133230A1 AR 133230 A1 AR133230 A1 AR 133230A1 AR P240101805 A ARP240101805 A AR P240101805A AR P240101805 A ARP240101805 A AR P240101805A AR 133230 A1 AR133230 A1 AR 133230A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- inhalation
- pharmaceutical
- pharmaceutically acceptable
- pharmaceutical formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En la presente se proporcionan formulaciones farmacéuticas del Compuesto A o sales farmacéuticamente aceptables del mismo para inhalación. También se proporcionan en la presente métodos para preparar y usar una formulación farmacéutica del Compuesto A para inhalación para el tratamiento de una enfermedad o una condición tal como fibrosis pulmonar idiopática. Reivindicación 1: Una formulación farmacéutica para inhalación, en donde la formulación comprende (a) Compuesto A o una sal farmacéuticamente aceptable del mismo, en donde el Compuesto A tiene una estructura de fórmula (1); y (b) un vehículo líquido; en donde el Compuesto A está presente en una cantidad de aproximadamente 0.01 mg/mL a aproximadamente 200 mg/mL. Reivindicación 64: Una composición farmacéutica para la preparación de la formulación farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 - 63, la composición farmacéutica comprende: (a) el Compuesto A o una sal farmacéuticamente aceptable del mismo, en donde el Compuesto A tiene una estructura de fórmula (1); (b) un agente amortiguador, un agente de ajuste del pH o ambos; y (c) opcionalmente, un agente de ajuste de osmolaridad, un edulcorante, un agente tensioactivo, un agente quelante, un antioxidante, un conservante o una combinación de los mismos. Reivindicación 68: Un dispositivo de inhalación que comprende la formulación farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 - 63 o la composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 64 - 67.Provided herein are pharmaceutical formulations of Compound A or pharmaceutically acceptable salts thereof for inhalation. Also provided herein are methods for preparing and using a pharmaceutical formulation of Compound A for inhalation for the treatment of a disease or condition such as idiopathic pulmonary fibrosis. Claim 1: A pharmaceutical formulation for inhalation, wherein the formulation comprises (a) Compound A or a pharmaceutically acceptable salt thereof, wherein Compound A has a structure of formula (1); and (b) a liquid carrier; wherein Compound A is present in an amount of about 0.01 mg/mL to about 200 mg/mL. Claim 64: A pharmaceutical composition for the preparation of the pharmaceutical formulation according to any one of claims 1-63, the pharmaceutical composition comprising: (a) Compound A or a pharmaceutically acceptable salt thereof, wherein Compound A has a structure of formula (1); (b) a buffering agent, a pH adjusting agent, or both; and (c) optionally, an osmolarity adjusting agent, a sweetener, a surfactant, a chelating agent, an antioxidant, a preservative, or a combination thereof. Claim 68: An inhalation device comprising the pharmaceutical formulation according to any one of claims 1 - 63 or the pharmaceutical composition according to any one of claims 64 - 67.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023107535 | 2023-07-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR133230A1 true AR133230A1 (en) | 2025-09-10 |
Family
ID=94281113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240101805A AR133230A1 (en) | 2023-07-14 | 2024-07-12 | PHARMACEUTICAL FORMULATIONS FOR INHALATION AND THEIR USES |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR133230A1 (en) |
| AU (1) | AU2024295749A1 (en) |
| TW (1) | TW202517265A (en) |
| WO (1) | WO2025016302A1 (en) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10092552B2 (en) * | 2011-01-31 | 2018-10-09 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| WO2020041631A1 (en) * | 2018-08-22 | 2020-02-27 | Avalyn Pharma Inc. | Specially formulated compositions of inhaled nintedanib and nintedanib salts |
| TR201900204A2 (en) * | 2019-01-08 | 2019-02-21 | Ali Raif Ilac Sanayi Ve Ticaret Anonim Sirketi | APPLICATION OF PIRPHENIDON BY INHALATION |
| US11795160B2 (en) * | 2019-02-22 | 2023-10-24 | Insilico Medicine Ip Limited | Kinase inhibitors |
| CN116348170A (en) * | 2020-09-22 | 2023-06-27 | 艾弗林制药有限公司 | Nebulizer device optimization and its use for improving aerosol parameter AMARKND |
| WO2022179529A1 (en) * | 2021-02-24 | 2022-09-01 | Insilico Medicine Ip Limited | Analogs for the treatment of disease |
| EP4298093A4 (en) * | 2021-02-24 | 2025-08-06 | Insilico Medicine Ip Ltd | Analogs for the treatment of disease |
| TW202416964A (en) * | 2022-08-24 | 2024-05-01 | 香港商英矽智能科技知識產權有限公司 | Methods of manufacturing kinase inhibitors |
-
2024
- 2024-07-12 WO PCT/CN2024/105133 patent/WO2025016302A1/en active Pending
- 2024-07-12 AU AU2024295749A patent/AU2024295749A1/en active Pending
- 2024-07-12 TW TW113126129A patent/TW202517265A/en unknown
- 2024-07-12 AR ARP240101805A patent/AR133230A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202517265A (en) | 2025-05-01 |
| AU2024295749A1 (en) | 2026-02-05 |
| WO2025016302A1 (en) | 2025-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2620413T3 (en) | Topical anthelmintic veterinary formulations | |
| MX2021008358A (en) | Lipids for lipid nanoparticle delivery of active agents. | |
| ES2638771T3 (en) | Aqueous pharmaceutical compositions containing borate-polyol complexes | |
| CO2023002852A2 (en) | Functionalized peptides as antiviral agents | |
| AR025434A1 (en) | PHARMACEUTICAL FORMULATION WITH BENZAMIDE DERIVATIVES CONTENT, WITH IMPROVED ORAL ABSORPTION AND SOLUBILITY | |
| AR052198A1 (en) | ANTI-BETA ANTIBODY FORMULATIONS | |
| AR033688A1 (en) | RECONSTITUABLE PARENTERAL COMPOSITION | |
| RU2015115127A (en) | LIQUID MEDICINAL COMPOSITIONS OF APIKSABAN | |
| AR119974A1 (en) | CONCENTRATED, STABLE RADIOPHARMACEUTIC COMPOSITION | |
| ES2902827T3 (en) | Osmolytes for the treatment of respiratory diseases of viral origin | |
| AR127247A1 (en) | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | |
| AR061166A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF PHENYLPHERINE | |
| JP2024061871A (en) | Ophthalmic Composition | |
| ES2295161T3 (en) | OPHTHALMIC SOLUTION. | |
| AR133230A1 (en) | PHARMACEUTICAL FORMULATIONS FOR INHALATION AND THEIR USES | |
| AR047469A1 (en) | ANTIMICROBIAL PRESERVANTS TO ACHIEVE A MULTIPLE DOSE FORMULATION USING BETA CYCLODEXTRINES FOR LIQUID DOSAGE FORMS | |
| CO6612211A2 (en) | Amide derivative that has a hypoglycemic action and / or a protective action of b or pancreas cells | |
| UY26459A1 (en) | 3,4-DIHIDROQUINAZOLINES 5,6-DISSTITUTED | |
| AR058619A1 (en) | PHARMACEUTICAL FORMULATION FOR THE SUPPLY OF INHIBITING COMPOUNDS OF THE THYROSINE KINASE RECEPTOR (RTKI) TO THE EYE | |
| PE20250267A1 (en) | SOLUBLE GUANYLYL CYCLASE STIMULATORS (sGC) | |
| ES2494668T3 (en) | Pharmaceutical compositions with phosphonium antimicrobial agents | |
| ES2732729T3 (en) | Oral topical aqueous pharmaceutical compositions of flurbiprofen and dexpanthenol | |
| ES2617235T3 (en) | Use of pidotimod to treat psoriasis | |
| AR128100A1 (en) | COMPOUNDS FOR THE TREATMENT OF HAIR LOSS | |
| JPWO2014119643A1 (en) | Clear aqueous solution |